Healthcare Companies Report Interim Data, Clinical Study Results, and Announcements - Research Report on Pfizer, Coronado Biosciences, Spectranetics, Celsion, and Intercept

NEW YORK, December 18, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Coronado Biosciences, Inc. (NASDAQ: CNDO), The Spectranetics Corporation (NASDAQ: SPNC), Celsion Corp. (NASDAQ: CLSN), and Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On December 13, 2013, Pfizer Inc.'s (Pfizer) stock was flat, touching the previous day close of $30.25 per share. Although, the Company's stock reflected a decrease of 3.48% over the past three trading day period, compared to the Dow Jones Industrial Average which went down by 1.36%, during the same three day trading period. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/d702_PFE

--

Coronado Biosciences, Inc. Research Report

On December 12, 2013, Coronado Biosciences, Inc. (Coronado Biosciences) announced that Dr. Eric Hollander presented interim data from his pilot study of oral TSO (Trichuris suis ova or CNDO-201). According to the Company, Dr. Hollander is a Clinical Professor of Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine of Yeshiva University, and Director of the Autism and Obsessive Compulsive Spectrum Program at Montefiore Medical Center and Einstein. The Company reported that during the study, 10 high-functioning adult autism spectrum disorder patients who were able to give informed consent to participate in the study, and who had a history of allergies and/or family history of immune-inflammatory illness were treated for 12 weeks with either TSO or placebo, followed by a 4-week washout phase and then 12 weeks of placebo or TSO (with the TSO dosage used in the study at 2,500 ova given once every two weeks). Additionally, the Company stated that the study is still ongoing and final results are expected in the middle of 2014. The Full Research Report on Coronado Biosciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/beea_CNDO

--

The Spectranetics Corporation Research Report

On December 13, 2013, The Spectranetics Corporation's (Spectranetics) stock reflected an increase of 2.74% and closed the day at $24.79 per share. Over the past three trading day period, the Company's stock went up by 2.23%, compared to the Nasdaq composite which went down by 1.47% during the same three day trading period. The Full Research Report on The Spectranetics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/82e6_SPNC

--

Celsion Corp. Research Report

On December 13, 2013, Celsion Corp. (Celsion) announced the presentation of the combined clinical study results from the Company's Phase I DIGNITY study and the Duke University sponsored Phase I trial of ThermoDox ® plus hyperthermia in Breast Cancer Recurrences at the Chest Wall (BCRCW) during Poster Session #4, held on the same day at the 2013 San Antonio Breast Cancer Conference, 7:30 a.m. to 9:00 a.m. (local time). According to the Company, the poster titled "Novel Targeted Therapy for Breast Cancer Chest Wall Recurrence: Low Temperature Liposomal Doxorubicin and Mild Local Hyperthermia" was presented by Professor Hope S. Rugo, MD, from University of California, San Francisco Comprehensive Cancer Center. The Full Research Report on Celsion Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/e8ef_CLSN

--

Intercept Pharmaceuticals, Inc. Research Report

On December 13, 2013, Intercept Pharmaceuticals, Inc.'s (Intercept Pharmaceuticals) stock went up by 4.38% as it closed the day at $62.92 per share. The Company's stock went up by 6.18% over the past three trading day period, compared to the Nasdaq composite which went down by 1.47% during the same three trading day period. The Full Research Report on Intercept Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/b477_ICPT

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED